Physician profile
Stephen Lieman
NPI 1114981727
$5,839.80
in general payments reported to CMS, 2019-2025
46 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $420 · 2021: $1,150 · 2022: $1,847 · 2023: $672 · 2024: $552 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.94 | 2019-2024 | |
| Astellas Pharma US INC | $695.31 | 2019-2024 | Myrbetriq, Xtandi, Veozah |
| Boston Scientific Corporation | $589.48 | 2019-2024 | Ams 700 |
| Pfizer INC. | $407.40 | 2019-2024 | |
| Antares Pharma, INC. | $269.59 | 2019-2024 | Xyosted |
| Urovant Sciences INC | $201.27 | 2021-2022 | |
| Accord Healthcare, INC. | $192.89 | 2022-2024 | |
| Endo Pharmaceuticals INC. | $176.04 | 2019-2024 | Xiaflex, Aveed |
| Verity Pharmaceuticals INC. | $173.78 | 2023-2025 | Trelstar |
| Sumitomo Pharma America, INC. | $169.09 | 2023-2024 | Gemtesa |
| Blue Earth Diagnostics | $165.98 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $133.36 | 2019-2024 | Adstiladrin |
| Astrazeneca Pharmaceuticals Lp | $132.10 | 2021 | |
| Agiliti Surgical, INC. | $129.31 | 2019 | |
| Myovant Sciences INC. | $122.82 | 2021-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lieman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.